Primary mediastinal large B-cell lymphoma differential diagnosis
|
Primary mediastinal large B-cell lymphoma Microchapters |
|
Differentiating Primary Mediastinal Large B-cell Lymphoma from other Diseases |
|---|
|
Diagnosis |
| Echocardiography and Ultrasound]] |
|
Treatment |
|
Case Studies |
|
Primary mediastinal large B-cell lymphoma differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Primary mediastinal large B-cell lymphoma differential diagnosis |
|
FDA on Primary mediastinal large B-cell lymphoma differential diagnosis |
|
CDC on Primary mediastinal large B-cell lymphoma differential diagnosis |
|
Primary mediastinal large B-cell lymphoma differential diagnosis in the news |
|
Blogs on Primary mediastinal large B-cell lymphoma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Badria Munir M.B.B.S.[2]
Overview
Primary mediastinal large B-cell lymphoma must be differentiated from other diseases that cause swollen face, superior vena cava syndrome, and fever, night sweats and weight loss such as hodgkin's lymphoma, thymoma, and other non hodgkin's lymphomas.
Differentiating [Disease name] from other Diseases
- Primary mediastinal large B-cell lymphoma must be differentiated from other diseases that cause swollen face, superior vena cava syndrome, and fever, night sweats and weight loss such as hodgkin's lymphoma, thymoma, and other non hodgkin's lymphomas.
- The differentiation is determined on the basis of biopsy findings and immunophenotype, which are as follows:
- Thymoma
- Thymic epithelial cells stain for epithelial markers such as keratin and epithelial membrane antigen.[1]
- Hodgkin's lymphoma[2]
- Thymic carcinoma
- Acute myeloid Leukemia
- Diffuse large B-cell lymphoma
- Involvement of bone marrow or distant lymph nodes is indicative of systemic DLBCL with secondary mediastinal involvement.
- Mediastinal germ cell tumor[5]
- Germ cell tumor markers such as beta-human chorionic gonadotropin [hCG] and alpha fetoprotein are positive.
References
- ↑ Kodama T, Watanabe S, Sato Y, Shimosato Y, Miyazawa N (January 1986). "An immunohistochemical study of thymic epithelial tumors. I. Epithelial component". Am. J. Surg. Pathol. 10 (1): 26–33. PMID 2420219.
- ↑ von Wasielewski R, Mengel M, Fischer R, Hansmann ML, Hübner K, Franklin J, Tesch H, Paulus U, Werner M, Diehl V, Georgii A (October 1997). "Classical Hodgkin's disease. Clinical impact of the immunophenotype". Am. J. Pathol. 151 (4): 1123–30. PMC 1858022. PMID 9327746.
- ↑ Suster S, Rosai J (February 1991). "Thymic carcinoma. A clinicopathologic study of 60 cases". Cancer. 67 (4): 1025–32. PMID 1991250.
- ↑ Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–405. doi:10.1182/blood-2016-03-643544. PMID 27069254.
- ↑ Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, Gray E, McKeever P, Hale J, Bailey S, Oakhill A (November 2000). "The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity". J. Clin. Oncol. 18 (22): 3809–18. doi:10.1200/JCO.2000.18.22.3809. PMID 11078494.